Jenny C. Chang, MD, director of the Methodist Cancer Center at Houston Methodist Hospital, discusses genomic testing in breast cancer.
Jenny C. Chang, MD
Advertisement
Articles by Jenny C. Chang, MD
Dr. Jenny Chang, from the Methodist Cancer Center, Discusses Combining HER2 Targeted Therapies
Advertisement
Latest Updated Articles
Dr. Chang on Genomic Testing in Breast CancerPublished: January 25th 2017 | Updated:
Dr. Chang on Combining HER2 Targeted TherapiesPublished: March 22nd 2012 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5